Azacitidine

Diffuse Glioma, H3 G34 Mutant

Andrew P. GrovesSmall moleculePhase 1Active

CC

41/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 81/ 100

Competitive context

9 Active assets in the Diffuse Glioma, H3 G34 Mutant cohort.

Asset / Sponsor	Phase	Rating
Ribociclib Nationwide Children's Hospital	Phase 2	CCC
Everolimus Nationwide Children's Hospital	Phase 2	CCC
Pegargiminase Sabine Mueller, MD, PhD	Phase 1/2	CCC
Defactinib Institute of Cancer Research, United Kingdom	Phase 1/2	CC
Avutometinib Institute of Cancer Research, United Kingdom	Phase 1/2	CC

View all 9 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BBB

Indicative ·

73 / 100

acute erythroid leukemiaDormant

BB

Indicative ·

71 / 100

non-small cell lung carcinomaDormant

BB

Indicative ·

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.